Home
Storia in 1 fonti
Biotech execs, academic expert lament impact of FDA turnover on rare disease drug development
How the ouster of key officials at the FDA has created anxiety and uncertainty for the developers of rare disease drugs.
Raccontata da
statnews.com
Timeline cronologica
- ·
Drugmakers guard IP more tightly amid China competition
The FDA's new path, the status of animal testing, and other biotech news from The Readout
- ·
Biotech execs, academic expert lament impact of FDA turnover on rare disease drug development
How the ouster of key officials at the FDA has created anxiety and uncertainty for the developers of rare disease drugs.
- ·
Dark times ahead at the FDA
It almost feels like the Trump administration is intentionally breaking the FDA, writes Lab Dish columnist Paul Knoepfler.